A Phase 3, Multicenter, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of TAK-085 in Subjects With Hypertriglyceridemia.

Trial Profile

A Phase 3, Multicenter, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of TAK-085 in Subjects With Hypertriglyceridemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary) ; Eicosapentaenoic acid
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 19 Mar 2012 Results presented at the 76th Annual Scientific Meeting of the Japanese Circulation Society.
    • 10 May 2011 Top-line results released in a Takeda and Pronova BioPharma media release.
    • 10 May 2011 Primary endpoint 'Triglyceride-levels' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top